Roche Moving Gantenerumab Into Phase 3 Prevention Trial for Early Alzheimer’s
Roche is launching a Phase 3 clinical trial to evaluate the ability of its investigational antibody therapy, gantenerumab, to slow Alzheimer’s progression in people with early signs of the disease, the company announced. Called SKYLINE (NCT05256134), the trial is now recruiting 1,200 cognitively unimpaired participants between…